Abstract
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects premenopausal women. It is a multifactorial disease that involves hyperandrogenism, ovulatory dysfunction, insulin resistance and genetic factors. Women with PCOS present with menstrual disorder, hirsutism, and obesity. Diagnosis of PCOS involves evidence of ovulation dysfunction, hyperandrogenism, either physical or biochemical, and ultrasonographic evaluation of the ovarian morphology. There is no single treatment for PCOS but rather it is a symptom-oriented management. Glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) are insulin sensitizers usually involved in the management of PCOS.
 Aim: This article aims to review the evidence regarding the role GLP-1 RAs in the management of polycystic ovary syndrome.
 Conclusion: GLP-1 RAs found to improve PCOS outcomes in the form of increasing menstrual frequency, reducing androgens levels, higher pregnancy rates, weight reduction, and improving insulin resistance. Mild and transient adverse events were observed such as nausea, diarrhea, headache, insomnia and mild hypoglycemic events. However, long term studies are required to assess long term effect of GLP-1 RAs and its safety during pregnancy.
Highlights
Polycystic ovary syndrome (PCOS) is a heterogeneous and heritable condition that characterized by androgen excess, menstrual dysfunction and ovulation dysfunction with a variable clinical presentation [1,2]
Endocrine aberrations found in PCOS are prolonged elevation of luteinizing hormone (LH) and Insulin resistance (IR) that leads to increase risk for diabetes mellitus (DM), obesity, high blood pressure and cardiovascular disease [6,7]
A higher rate of pregnancy rate per embryo transfer observed after a pre-conceptional intervention with liraglutide in patients attempting in-vitro fertilization (IVF)
Summary
Polycystic ovary syndrome (PCOS) is a heterogeneous and heritable condition that characterized by androgen excess, menstrual dysfunction and ovulation dysfunction with a variable clinical presentation [1,2]. It represents the single most common endocrine-metabolic disorder in reproductive-aged women that starts as early as menarche [3]. Endocrine aberrations found in PCOS are prolonged elevation of luteinizing hormone (LH) and Insulin resistance (IR) that leads to increase risk for diabetes mellitus (DM), obesity, high blood pressure and cardiovascular disease [6,7]. The aim of this review to summarize the evidence in the literature about the role of GLP-1 RAs in the management of PCOS
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
